Tests a genetic-review service to guide treatment choice in advanced cancers
Tests a genetic-review navigation service in adults with advanced breast, lung, colorectal or bladder cancer.
Key facts
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Where
- Chapel Hill, United StatesSee the site
- Trial code
- Registry title
- PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 27 Jun 2025
- Expected to end
- Jun 2028
- Type of study
- Interventional
- Treatments tested
- Expert Review
- Blood or tissue samples collection.
- The Precision Oncology Navigation
- Record updated
- 14 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV lung, colorectal, breast or bladder cancer who can still do most daily activities. A navigator and an expert pharmacist will review their tumor gene test results.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Documented stage IV solid tumor: non-small cell lung cancer, colorectal cancer, breast cancer or bladder cancer.
- Earlier treatment
- The treating provider plans to use the gene test results in first- or second-line treatment of the metastatic cancer.
- Biomarker or test result
- A genomic tumor test must not have been ordered yet, or must have been ordered but not yet resulted.
Main reasons for not taking part
- An active second cancer at the same time
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information
- Subjects are willing and able to comply with study procedures based on the judgment of the investigator
- Age ≥ 18 years at the time of consent
- ECOG or Karnofsky Performance Status of 0-2
- Documented Stage IV solid tumor malignancy: NSCLC, CRC, Breast or Bladder Cancer
- The treating provider deems Next Generation Sequencing (NGS) testing appropriate and plans to consider results in either first- or second-line therapy in the metastatic setting
- A genomic tumor test has not been ordered or has been ordered but not resulted
Who cannot take part
- Subjects with an active concurrent malignancy
Other criteria
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below
Where in United States
- Lineberger Comprehensive Cancer Center, University of North CarolinaChapel Hill, United StatesContact: Carrie Lee, MDTaking people
About the trial
What the trial wants to find out
This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for patients with stage IV solid tumor malignancies (breast, lung, colorectal, and bladder cancers).
Read full original descriptionShow less
The purpose of this study is to investigate whether intervention from a centralized precision oncology navigator and expert review of NGS results by the precision oncology pharmacist will increase ordering of Level 1/2 genome informed therapy (GIT) compared to an estimated historical rate of 15%. Secondary endpoints will assess the impact of a centralized precision oncology navigator and expert review of NGS results on enrollment in biomarker-directed clinical trials and overall survival at 2 years after return of NGS results. The study will take approximately 12 months for enrolment and 2 years of follow-up after the date of NGS results.
The group in the trial
- The potential candidates for genome-informed targeted therapyOther group
Potential candidates have a stage IV solid tumor malignancy (breast, lung, colorectal, and bladder cancer) for whom NGS testing is planned to be obtained before first or second-line therapy.
Treatment: Expert Review, Blood or tissue samples collection., and The Precision Oncology Navigation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Plain-language title
- Tests a genetic-review service to guide treatment choice in advanced cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 July 2026